Reported med-tech deal value in the first seven months of 2025 remained sharply subdued, totaling just $657.44 million across ...

The U.S. FDA has given a swift and full approval to Precigen Inc.’s gene therapy, Papzimeos (zopapogene imadenovec), for treating adults with recurrent respiratory papillomatosis (RRP), a rare and ...